Anthony Perissinotti, PharmD, BCOP

Clinical Pharmacist Specialist: Hematology
Clinical Team Leader: Hematology/Oncology Pharmacy
Adjunct Clinical Assistant Professor in Pharmacy
Rotation(s) Offered: Inpatient Adult Hematology
ajperis@med.umich.edu
Articles ↓

Biography

I primarily cover patients with acute leukemias (AML and ALL), aggressive lymphomas (burkitt and DLBCL), and other challenging hematologic malignancies. I am the clinical team lead of hematology/Oncology.

Pharmacy School Attended: Wayne State University (2010)

Other Training:

  • PGY1 Pharmacy: The Detroit Medical Center –Harper University Hospital (2011)
  • PGY2 Oncology: The University of Texas –MD Anderson Cancer Center (2012)

Areas of Interest

Acute Leukemias, Asparaginase, Immunocompromised infectious diseases

Honors & Awards

American Society of Hematology (ASH)Abstract Achievement Award, 2014

Published Articles or Reviews

  • Reid JH, Durant KM, Chen SL, Perissinotti AJ, King R, Khoriaty R, Marini BL. Role of caplacizumabin the treatment of acquired thrombotic thrombocytopenic purpura [published online ahead of print, 2020 Jun 30]. J Oncol Pharm Pract. 2020;1078155220934862. doi:10.1177/1078155220934862
  • Perissinotti AJ. Cost considerations in the first-line treatment of advanced Hodgkin lymphoma. Lancet Haematol. 2020 Feb;7(2):e91-e93.
  • Reid JH, Marini BL, Nachar VR, Brown AM, Devata S, Perissinotti AJ. Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. Crit Rev Oncol Hematol. 2020;148:102897. doi:10.1016/j.critrevonc.2020.102897
  • Weis TM, Marini BL, Nachar VR, Brown AM, Phillips TJ, Brown J, Wilcox RA, Kaminski MS, Devata S, Perissinotti AJ. Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. Leuk Lymphoma. 2019 Dec 26;1-7. doi: 10.1080/10428194.2019.1703969. [Epub ahead of print]. PMID: 31876206.
  • Hoylman E, Brown A, Perissinotti AJ, Marini BL, Pianko M, Ye JC, Campagnaro E, Nachar VR. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2019 Nov 18;1-8. doi: 10.1080/10428194.2019.1688324. [Epub ahead of print]. PMID: 31739729.
  • Reid JH, Perissinotti AJ,Benitez L, Bixby DL, Burke P, Pettit K, Marini BL. Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. Leuk Lymphoma. 2019 Nov 18;1-7. doi: 10.1080/10428194.2019.1691199. [Epub ahead of print]. PMID: 31739707.
  • Alsawah F, Benitez L, Choi S, Marini B, Perissinotti A, Skyles A, Burke P, Pettit K, Crouch A, Fox H, Bixby D. Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. Blood Adv. 2019 Nov 12;3(21):3333-3336. doi: 10.1182/bloodadvances.2019000289. PMID: 31698446; PMCID: PMC6855106.
  • Merz LE, Perissinotti AJ, Marini BL, Burke PW, Crouch A, Erba HP, Bixby D. Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM. Clin Lymphoma Myeloma Leuk. 2019 Sep 28. pii: S2152-2650(19)32002-6. doi:10.1016/j.clml.2019.09.615. [Epub ahead of print] PubMed PMID: 31711889.
  • Weis TM, Perissinotti AJ, Nachar VR, Brown A, Phillips TP, Marini BL. Dosing vincristine in DA-EPOCH-R: to cap or not to cap? J Clin Oncol. 2019. J Clin Oncol. 2019 Sep 18:JCO1901259. doi: 10.1200/JCO.19.01259. [Epub ahead of print] PubMed PMID: 31532723.
  • Marini BL, Perissinotti AJ, Bixby DL, Burke PW, Pettit KM, Benitez LL. Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? 10 July 2019. https://doi.org/10.1002/cncr.32381
  • Weis TM, Marini BL, Bixby DL, Perissinotti AJ. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2019 Jun 28;141:125-138. doi: 10.1016/j.critrevonc.2019.06.011. [Epub ahead of print]
  • Patel HP, Perissinotti AJ, Patel TS, Bixby DL, Marshall VD, Marini BL. Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy. Open Forum Infect Dis. 2019 Apr 12;6(5):ofz176. doi: 10.1093/ofid/ofz176.
  • Marini BL, Brown J, Benitez L, Walling E, Hutchinson RJ, Mody R, Jasty Rao R, Slagle L, Bishop L, Pettit K, Bixby DL, Burke PW, Perissinotti AJ. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leuk Lymphoma. 2019 May 17:1-15. doi: 10.1080/10428194.2019.1608530. [Epub ahead of print]
  • Reid JH, Marini BL, Nachar VR, Devata S, Perissinotti AJ. PET-guided, BEACOPP(escalated) therapy in advanced Hodgkin lymphoma. Lancet Oncol. 2019 Apr;20(4):e188. doi: 10.1016/S1470-2045(19)30081-6.
  • Chappell G, Geer M, Gatza E, Braun T, Churay T, Brisson J, Bixby D, Marini B, Perissinotti A, Frame D, Parkin B, Reddy P, Magenau J, Choi SW. Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. Bone Marrow Transplant. 2019 Feb 26. doi: 10.1038/s41409-019-0493-5. [Epub ahead of print]
  • Robinson AC, Marini BL, Pettit KM, Perissinotti AJ. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction. J Oncol Pharm Pract. 2019 Feb 13:1078155219829534.
  • Cheung E, Perissinotti AJ, Bixby DL, Burke PW, Pettit KM, Benitez LL, Brown J, Scappaticci GB, Marini BL. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann Hematol. 2019 Jan 21. doi: 10.1007/s00277-019-03606-0. [Epub ahead of print]
  • Perissinotti AJ, Marini BL. Managing liver dysfunction in haematology patients: Switch antifungals, or use the tincture of time? Mycoses. 2018 Nov 26. doi: 10.1111/myc.12871. [Epub ahead of print]
  • VulajV, Perissinotti AJ, Uebel JR, Nachar VR, Scappaticci GB, Crouch A, Bixby DL, Burke PW, Maillard I, Talpaz M, Marini BL. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leuk Res. 2018 [published online 1 June 2018]. https://doi.org/10.1016/j.leukres.2018.05.011
  • Ettleson M, Bongers KS, Vitale K, Perissinotti AJ, Phillips T, Marini BL. Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. J Oncol Pharm Pract. 2018 Jan 1:1078155217754244.
  • Scappaticci GB, Marini BL, Nachar VR, Uebel JR, Vulaj V, Crouch A, Bixby DL, Talpaz M, Perissinotti AJ. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. Ann Hematol. 2018 Apr;97(4):573-584. doi: 10.1007/s00277-017-3217-1. Epub 2017 Dec 29.
  • Nachar VR, Perissinotti AJ, Scappaticci GB, Bixby DL, Marini BL. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment. Leuk Res. 2017 Dec;63:56-61. doi: 10.1016/j.leukres.2017.10.017. [Epub ahead of print]
  • Neumann DR, Marini BL,Phillips TJ, Wilcox RA, Mayer TL, Brown A, Perissinotti AJ.Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma. Leuk Lymphoma. 2017 Nov 6:1-10. doi: 10.1080/10428194.2017.1393672. [Epub ahead of print]
  • Salzer W, Bostrom B, Messinger Y, Perissinotti AJ, Marini B. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2017 Oct 18:1-10. doi: 10.1080/10428194.2017.1386305. [Epub ahead of print]
  • Perissinotti AJand Marini BL. Real-life challenges to the use of antifungal agents in hematology patients. Curr Fungal Infect Rep. 2017 Oct;11: 229-241. https://doi.org/10.1007/s12281-017-0303-8
  • Tang LA, Marini BL,Benitez L, Nagel JL, Miceli M, Berglund C, Perissinotti AJ.Risk factors for subtherapeutic levels of posaconazole tablet. J Antimicrob Chemother. 2017 Oct 1;72(10):2902-2905. doi: 10.1093/jac/dkx228. [Epub ahead of print]
  • Marini BL, Perissinotti AJ,Bixby DL, Brown J, Burke PW. Catalyzing improvements in ALL therapy with asparaginase. Blood Rev. 2017 Sep;31(5):328-338. [Epub ahead of print]
  • Rausch CR, Marini BL,Benitez LL, Elias A, Burke PW, Bixby D, Perissinotti AJ. PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2017 Jul 18:1-8. [Epub ahead of print]
  • Herc ES, Kauffman CA, Marini BL,Perissinotti AJ, Miceli MH. Daptomycin nonsusceptible vancomycin resistant Enterococcus bloodstream infections in patients with hematological malignancies: risk factors and outcomes. Leuk Lymphoma. 2017 Apr 12:1-7. [Epub ahead of print]
  • Scappaticci GB, Perissinotti AJ,Nagel JL, Bixby DL, Marini BL.Risk factors and impact of Clostridium difficile recurrence on haematology patients. J Antimicrob Chemother. 2017 Feb 10.
  • Boyd AM, Perissinotti AJ, Nagel JL, Frame DG, Marini BL. Risk factors for cefepime nonsusceptible Gram-negative infections in allogeneic hematopoietic cell transplant recipients. J Oncol Pharm Pract. 2017 Jan 1:1078155217731507. doi: 10.1177/1078155217731507. [Epub ahead of print]
  • Shaikh SA, Marini BL, Hough SM, Perissinotti AJ. Rational use of rasburicase for the treatment and management of tumor lysis syndrome. J Oncol Pharm Pract. 2017 Jan 1:1078155216687152. [Epub ahead of print]
  • DasGupta RK, Marini BL, Rudoni J, Perissinotti AJ. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. J Oncol Pharm Pract. 2017 Jan 1:1078155217713363. [Epub ahead of print]
  • Barker JA, Marini BL, Bixby D, Perissinotti AJ. Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. J Oncol Pharm Pract. 2016 Dec;22(6):811-815.
  • Marini BL,Sun Y, Burke PW, Perissinotti AJ.Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome. J Oncol Pharm Pract. 2016 Oct 31. [Epub ahead of print]
  • Ganti BR, Marini BL, Nagel J, Bixby D, Perissinotti AJ.Impact of Antibacterial Prophylaxis during Reinduction Chemotherapy for Relapse/Refractory Acute Myeloid Leukemia. Support Care Cancer. 2016 Oct 14. [Epub ahead of print]
  • Marini BL, Samanas L, Perissinotti AJ. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. J Oncol Pharm Pract. 2016 Jun 29. [Epub ahead of print]
  • Marini BL, Wechter AR, Burke PW, Bixby D, Perissinotti AJ. Minimizing waste during preparation of blinatumomab infusions. Am J Health Syst Pharm. 2016 Jan 15;73(2):19-20.
  • Benitez L, Perissinotti AJ, Santarossa M, Marini BL.Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. Pediatr Blood Cancer. 2015 Jun;62(6):1115.
  • Miceli MH, Perissinotti AJ, Kauffman CA, Couriel DR. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses. 2015 Jul;58(7):432-6. doi: 10.1111/myc.12339.
  • Perissinotti AJ, Gulbis A, Shpall EJ, Howell J.Characterizing human herpes virus 6 following hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2015 Apr;21(2):85-92. doi: 10.1177/1078155213519837.